Phase 3 study demonstrated that efanesoctocog alfa met both primary and secondary endpointsOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.